Publicidad

Correlación entre gammagrafía ósea y PET-CT con 18F-FDG para la evaluación de enfermedad ósea metastásica en pacientes con cáncer de mama

Referencias

  1. Estadísticas a propósito del día mundial contra el cáncer. Instituto Nacional de Geografía y Estadística (INEGI) 2013. México, D.F.
  2. Encuesta Nacional de Salud y Nutrición (ENSANUT) 2012.
  3. Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nuc Med 2005; 35:84-99.
  4. National Comprehensive Cancer Network (NCCN) guideline, version 3.2014.
  5. Roberts C, Daffner R, Weissman B. ACR appropriateness criteria on metastatic bone disease. J Am Coll Radiol 2010; 7:400-9.
  6. Toung P, Lemeshko S, Mahoney M, et al. ACR Appropriateness criteria stage I breast carcinoma. J Am Coll Radiol 2012; 9:463-7.
  7. Ohta M, Tokuda Y, Suzuki Y, et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99mTc-MDP bone scintigraphy. Nucl Med Commun 2001; 22:875-9.
  8. Yang S, Liang J, Lin F, et al. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 2002; 128:325-8.
  9. Rong J, Wang S, Young M, et al. Comparison of 18FDG PET-CT and bone scintigraphy for detection of bone metastases in breast cancer patients. A meta-analysis. Surg Oncol 2013; 22:86-91.
  10. Hahn S, Heusner T, Kümmel S, et al. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer. Acta Radiol 2011; 52:1009.
  11. Shie P, Cardarelli R, Brandon D, et al. Positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer. Clin Nucl Med 2008; 33:97-101.
  12. Morris P, Lynch C, Feeney J, et al. Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. J Clin Oncol 2010; 28:3154-9.
  13. Ben-Haim S, Israel O. Breast cancer: Role of SPECT and PET imaging bone metastases. Sem Nucl Med 2009; 39:408-15.
  14. Abe K, Sasaki M, Kuwabara Y, et al. Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med 2005; 19:573-9.
  15. Nakai T, Okuyama C, Kubota T, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imag 2005; 32:1253-8.
  16. Uematsu T, Yuen S, Yukisawa S, et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. Am J Roentgenol 2005; 184:1266-73.
  17. Du Y, Cullum I, Illidge T, et al. Fusion of metabolic function and morphology: sequential [18F]Fluordeoxyglucose Positron-Emission Tomography / Computed Tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol 2007; 25:3440-7.